IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1967 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded163    
    Comments [Add]    

Recommend this journal


Year : 1997  |  Volume : 29  |  Issue : 5  |  Page : 314-317

A comparative double blind randomised study of gemfibrozil and lovastatin in hypercholesterolemia

Correspondence Address:
Prabha MR Adhikari

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Objective: To evaluate the safety and efficacy of lovastatin in comparison with gemfibrozil in 60 Indian patients with primary hypercholesterolemia (250-350 mg/dL). Methods: After excluding patients with exclusion criteria, 60 adult patients were randomly allocated to the study medication which contained either lovastatin tablets 20 mg or gemfibrozil capsules of 300 mg for 4 weeks and the lipoprotein profile was estimated before and after the treatment. Results: Of the 60 patients, only 44 were available for efficacy analysis, 18 in gemfibrozil group and 26 in lovastatin group and the rest were drop outs. There was a statistically significant reduction in LDL cholesterol from base line value in lovastatin group (32.8%) in comparison with gemfibrozil group (20.35%). Lovastatin was better in raising HDL cholesterol from the base line value (16.3%) in comparison with gemfibrozil (-1.7%) Although there was better reduction in total cholesterol and triglycerides with lovastatin group, this was statistically not significant. Gastrointestinal side effects severe enough to warrant drug withdrawal occurred only in 3.3% (n=1) of lovastatin group as against 33.3% (n=9) of gemfibrozil group. Conclusion: Lovastatin is superior to gemfibrozil in lowering LDL cholesterol and raising HDL cholesterol and it is better tolerated.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow